Finance

Lists
SHPMY:OTCMKTS
Shanghai Pharmaceuticals Holdings ADR
USD 7,08
0,00%
(0,00) 1D
1 Okt., 14:50:24 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SHPMY...
Mkt. cap
63,19 mjd
Avg. vol.
116,00
Volume
2,00
52-wk high
USD 8,23
52-wk low
USD 6,41
Beta
0,58
Shares outstanding
183,81 m
No. of employees
49 k
Mkt. cap
63,19 mjd
Avg. vol.
116,00
Volume
2,00
52-wk high
USD 8,23
52-wk low
USD 6,41
Beta
0,58
Shares outstanding
183,81 m
No. of employees
49 k
News stories
From web sources and news partners
Profile
Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia
About Shanghai Pharmaceuticals Holdings ADR
CEO-
Employees48,6 k
Founded18 Jan. 1994
Headquarters-
SectorHealth care provider
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
73,48 mjd
68,51 mjd
75,26 mjd
72,21 mjd
Cost of goods sold
66,03 mjd
60,55 mjd
67,17 mjd
64,09 mjd
Cost of revenue
66,03 mjd
60,55 mjd
67,17 mjd
64,09 mjd
Research and development expenses
556,53 m
824,53 m
468,22 m
502,64 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,70 mjd
4,97 mjd
4,59 mjd
4,65 mjd
Operating expense
5,58 mjd
5,91 mjd
5,47 mjd
5,55 mjd
Total operating expenses
71,60 mjd
66,47 mjd
72,63 mjd
69,64 mjd
Operating income
1,88 mjd
2,04 mjd
2,63 mjd
2,57 mjd
Other non operating income
-84,84 m
-63,65 m
-47,88 m
-7,43 m
EBT including unusual items
1,48 mjd
1,52 mjd
2,42 mjd
3,21 mjd
EBT excluding unusual items
1,61 mjd
1,44 mjd
2,27 mjd
3,03 mjd
Income tax expense
485,91 m
534,14 m
569,09 m
720,64 m
Effective tax rate
32,89%
35,10%
23,52%
22,43%
Other operating expenses
129,62 m
271,29 m
132,16 m
186,62 m
Net income
688,20 m
577,49 m
1,42 mjd
2,09 mjd
Net profit margin
0,94%
0,84%
1,88%
2,89%
Earnings per share
-
-
-
-
Interest and investment income
206,57 m
-
38,70 m
873,52 m
Interest expense
-393,02 m
-470,36 m
-347,64 m
-358,39 m
Net interest expenses
-186,45 m
-470,36 m
-308,94 m
515,13 m
Depreciation and amortization charges
-
-
-
-
EBITDA
2,26 mjd
2,54 mjd
3,12 mjd
3,07 mjd
Gain or loss from assets sale
39,99 m
-157,15 m
-
-179,70 m
AI content may include mistakes. Learn more
Google-programme